Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company (“The Chemours” or the “Company”) (NASDAQ: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012875616/en/
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants' overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants' financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results, including a reduction of its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously), and management admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." On this news, Chemours's stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding The Chemours’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the The Chemours class action, go to www.faruqilaw.com/CC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the The Chemours Securities Class Action Lawsuit:
What is the The Chemours securities fraud lawsuit about?
The lawsuit alleges that The Chemours Company ("Chemours") and certain of its officers and directors made materially false and/or misleading statements and failed to disclose material information to investors during the Class Period. Specifically, the complaint alleges that Defendants materially overstated aftermarket demand for their Opteon products and concealed that demand was declining due to Defendants' alleged overselling of those products in the preceding fiscal year. As a result of these allegedly undisclosed issues, the complaint further alleges that Defendants' financial guidance for fiscal year 2026 was unreliable. On August 4, 2026, after market hours, Chemours allegedly revealed the truth when it announced reduced full-year adjusted EBITDA guidance and management acknowledged that aftermarket customers had built excess inventory following an initial channel fill, creating an oversupplied channel heading into 2026.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired the common stock of The Chemours Company (NASDAQ: CC) on the open market between February 20, 2026 and August 4, 2026, inclusive, may be eligible to participate in this lawsuit. The class period encompasses all qualifying purchases made during those dates, and eligible investors are encouraged to review the complaint and assess their potential claims. Importantly, investors do not need to seek appointment as lead plaintiff in order to participate in the case or share in any potential recovery. Any investor who believes they may have suffered losses as a result of the alleged misconduct is encouraged to contact counsel to learn more about their rights and options.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of counsel. Any member of the proposed class may move the court for appointment as lead plaintiff, and the court will typically appoint the applicant or group of applicants who demonstrate the largest financial interest in the relief sought and who otherwise satisfy the requirements of the applicable law. The deadline to file a motion for appointment as lead plaintiff in this action is December 7, 2026. Critically, an investor need not serve as lead plaintiff to be a member of the class or to share in any recovery that may be obtained; class membership and any resulting recovery are available to all eligible investors regardless of whether they seek a leadership role in the case.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased The Chemours securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261012875616/en/
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements
Contacts
Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)
